Literature DB >> 7442081

[Comparison of oral diazoxide and minoxidil in refractory hypertension].

A Meier, P Weidmann, Z Glück, G Keusch, M Grimm, I Minder, F C Reubi.   

Abstract

The efficacy and side effects of two potent vasodilatators, namely diazoxide and minoxidil given orally, were compared in 11 patients who had hypertension refractory to conventional drug treatment. The latter included diuretics, betablockers and/or sympatholytics, and either dihydralazine or prazosin. In a crossover approach, dihydralazine and prazosin were withdrawn and replaced by diazoxide or minoxidil. In nine patients the diazoxide phase preceded the minoxidil treatment, while in two it followed minoxidil treatment. Before introduction of the more potent vasodilators blood pressure averaged 181/107 mm Hg in the supine and 161/103 mm Hg in the upright position. Both, oral diazoxide (median dose 400 mg/d( and minoxidil (medium dose 17.5 mg/d) produced similar decreases (p < 0.02) in mean arterial pressure (-15%) in the supine and (-11 vs. -12%) in the upright position. They caused a comparable tendency for sodium retention and weight gain which could be satisfactorily controlled with increased diuretic therapy, except in one patient. Hypertrichosis occurred with both drugs, but tended to be somewhat milder with diazoxide. Electrocardiograms remained generally unchanged. Plasma glucose levels were increased during diazoxide treatment in six patients necessitating interruption of this therapy in four patients. It is concluded that the antihypertensive potency and most side effect of orally administered diazoxide are comparable to those of minoxidil, except for diazoxide-related hyperglycemia which may limit the use of this substance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7442081     DOI: 10.1007/bf01478605

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  31 in total

Review 1.  Minoxidil therapy in refractory hypertension analysis of 155 patients.

Authors:  G W Keusch; P Weidmann; V Campese; D B Lee; A T Upham; S G Massry
Journal:  Nephron       Date:  1978       Impact factor: 2.847

2.  Intravenous diazoxide therapy in hypertensive crisis.

Authors:  W J McDonald; G Smith; J W Woods; H M Perry; B D Danielson
Journal:  Am J Cardiol       Date:  1977-09       Impact factor: 2.778

Review 3.  Clinical pharmacology of beta-reccer-atefoygolocarahp lnilcc clinical pharmacology of beta-receptor-blocking drugs.

Authors:  C T Dollery; J W Paterson; M E Conolly
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

4.  Oral diazoxide in uncontrolled malignant hypertension.

Authors:  P Fang; I MacDonald; M Laver; A Hua; P Kincaid-Smith
Journal:  Med J Aust       Date:  1974-10-26       Impact factor: 7.738

5.  Effect of treatment on morbidity in hypertension. Veterans Administration Cooperative Study on Antihypertensive Agents. Effect on the electrocardiogram.

Authors:  P F Poblete; M C Kyle; H V Pipberger; E D Freis
Journal:  Circulation       Date:  1973-09       Impact factor: 29.690

6.  Minoxidil--an alternative to nephrectomy for refractory hypertension.

Authors:  W A Pettinger; H C Mitchell
Journal:  N Engl J Med       Date:  1973-07-26       Impact factor: 91.245

7.  Further studies on diazoxide suppression of insulin release from abnormal and normal islet tissue in man.

Authors:  S S Fajans; J C Floyd; C A Thiffault; R F Knopf; T S Harrison; J W Conn
Journal:  Ann N Y Acad Sci       Date:  1968-04-11       Impact factor: 5.691

8.  Diazoxide in treatment of primary pulmonary hypertension.

Authors:  S W Wang; J E Pohl; D J Rowlands; E G Wade
Journal:  Br Heart J       Date:  1978-05

9.  Treatment of severe hypertension with minoxidil: advantages and limitations.

Authors:  V M Campese; D Stein; V DeQuattro
Journal:  J Clin Pharmacol       Date:  1979-04       Impact factor: 3.126

10.  Individual titration of diazoxide dosage in the treatment of severe hypertension.

Authors:  C V Ram; N M Kaplan
Journal:  Am J Cardiol       Date:  1979-03       Impact factor: 2.778

View more
  4 in total

1.  Comparative evaluation of the new vasodilator carprazidil and minoxidil in the treatment of moderate to severe hypertension.

Authors:  M G Bianchetti; P Weidmann; K Boehringer; L Link; H Schiffl; C Beretta-Piccoli; J P Colombo
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

2.  Chronic treatment with the new potent vasodilator Ro 12-4713 in moderate to severe hypertension: effects on blood pressure, endocrine function, sodium and plasma volume.

Authors:  M Grimm; P Weidmann; A Meier; H Schiffl; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

3.  Catecholamines, renin, aldosterone, and blood volume during chronic minoxidil therapy.

Authors:  A Meier; P Weidmann; W H Ziegler
Journal:  Klin Wochenschr       Date:  1981-11-16

Review 4.  Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer.

Authors:  R J Klement; M K Fink
Journal:  Oncogenesis       Date:  2016-02-15       Impact factor: 7.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.